Re: ARC-520 Phase 1 - the reply I got from Arrowhead...
Here's the reply I got from Arrowhead today:
Thanks for your interest. There has been some speculation about the Phase 1 trial based on an update that was made in February to the clinical trials.gov entry for ARC-520 that changed estimated enrollment to 48. This does not reflect any change to previous guidance we have given about retaining the right and flexibility to add additional cohorts to the Phase 1 if we think it will be helpful for the program. It is still an open study, so I cant comment specifically about any actions or plans beyond the guidance we have given.
Vincent Anzalone, CFA